167 related articles for article (PubMed ID: 16858151)
1. The diagnosis of malignancy in effusion cytology: a pattern recognition approach.
Pereira TC; Saad RS; Liu Y; Silverman JF
Adv Anat Pathol; 2006 Jul; 13(4):174-84. PubMed ID: 16858151
[TBL] [Abstract][Full Text] [Related]
2. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
3. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Accuracy of a Limited Immuno-panel of Calretinin and Ber-EP4 for Diagnosis of Malignant Effusions.
Khurram N; Anis T; Yusuf NW
J Coll Physicians Surg Pak; 2019 Jan; 29(1):33-36. PubMed ID: 30630566
[TBL] [Abstract][Full Text] [Related]
5. Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.
Conner JR; Cibas ES; Hornick JL; Qian X
Cancer Cytopathol; 2014 Aug; 122(8):586-95. PubMed ID: 25044880
[TBL] [Abstract][Full Text] [Related]
6. An Updated Contextual Approach to Mesothelial Proliferations in Pleural Effusion Cytology Leveraging Morphology, Ancillary Studies, and Novel Biomarkers.
Miller LJ; Holmes IM; Lew M
Arch Pathol Lab Med; 2024 Apr; 148(4):409-418. PubMed ID: 37622452
[TBL] [Abstract][Full Text] [Related]
7. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
8. Ancillary studies in pleural, pericardial, and peritoneal effusion cytology.
Sundling KE; Cibas ES
Cancer Cytopathol; 2018 Aug; 126 Suppl 8():590-598. PubMed ID: 30156768
[TBL] [Abstract][Full Text] [Related]
9. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
10. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.
Davidson B; Stavnes HT; Hellesylt E; Hager T; Zeppa P; Pinamonti M; Wohlschlaeger J
Hum Pathol; 2016 Jan; 47(1):104-8. PubMed ID: 26520416
[TBL] [Abstract][Full Text] [Related]
11. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology.
Jo VY; Cibas ES; Pinkus GS
Cancer Cytopathol; 2014 Apr; 122(4):299-306. PubMed ID: 24421209
[TBL] [Abstract][Full Text] [Related]
12. Assessment of immunocytochemical and histochemical stainings in the distinction between reactive mesothelial cells and adenocarcinoma cells in body effusions.
Chen CJ; Chang SC; Tseng HH
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Sep; 54(3):149-55. PubMed ID: 7954054
[TBL] [Abstract][Full Text] [Related]
13. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
[TBL] [Abstract][Full Text] [Related]
15. Ultrastructure of pleural mesothelioma and pulmonary adenocarcinoma in malignant effusions as compared with reactive mesothelial cells.
Sakuma N; Kamei T; Ishihara T
Acta Cytol; 1999; 43(5):777-85. PubMed ID: 10518130
[TBL] [Abstract][Full Text] [Related]
16. EZH2, a unique marker of malignancy in effusion cytology.
Jiang H; Gupta R; Somma J
Diagn Cytopathol; 2014 Feb; 42(2):111-6. PubMed ID: 23636867
[TBL] [Abstract][Full Text] [Related]
17. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
Cakir E; Demirag F; Aydin M; Unsal E
Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123
[TBL] [Abstract][Full Text] [Related]
18. Lamellar Inclusions within Hyperplastic Endoplasmic Reticulum in Benign Mesothelial Cells.
Haefliger S; Jain D; Menter T; Vlajnic T; Savic Prince S; Hopfer H; Mihatsch MJ; Bubendorf L
Acta Cytol; 2020; 64(6):572-576. PubMed ID: 32599592
[TBL] [Abstract][Full Text] [Related]
19. Value of antimesothelioma HBME-1 in the diagnosis of inflammatory and malignant pleural effusions.
Mocanu L; Cîmpean AM; Raica M
Rom J Morphol Embryol; 2006; 47(4):351-5. PubMed ID: 17392981
[TBL] [Abstract][Full Text] [Related]
20. Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis.
Stevens MW; Leong AS; Fazzalari NL; Dowling KD; Henderson DW
Diagn Cytopathol; 1992; 8(4):333-41. PubMed ID: 1638933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
